With Kite’s PDUFA date looming, federal court tosses Juno’s CAR-T patent challenge — for now
Juno Therapeutics $JUNO was spoiling to battle rival CAR-T developer Kite Pharma $KITE in court over claims that its lead therapy had infringed on its patent. But today Juno says that the suit was thrown out after the U.S. District Court for the District of Delaware determined that it lacked jurisdiction until after an approval occurs.
According to Juno, the court determined that there was no evidence that an FDA approval of Kite’s therapy – axicabtagene ciloleucel, or KTE-C19 – “is imminent or even certain.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.